Sunho Biologics, Inc.（“Sunho Biologics”， Stock Code: 02898.HK）completed its IPO and listing on the Main Board of Hong Kong Stock Exchange on May 24, 2024，as China’s “first Antibody Cytokine Stock”.

As the PRC legal counsel of the issuer, and the IP legal counsel, Jingtian & Gongcheng has provided high-quality legal services for the listing project throughout the whole process.